Author:
de Vries Elisabeth G. E.,Kist de Ruijter Laura,Lub-de Hooge Marjolijn N.,Dierckx Rudi A.,Elias Sjoerd G.,Oosting Sjoukje F.
Publisher
Springer Science and Business Media LLC
Reference143 articles.
1. Cottingham, M. D., Kalbaugh, C. A. & Fisher, J. A. Tracking the pharmaceutical pipeline: clinical trials and global disease burden. Clin. Transl Sci. 7, 297–299 (2014).
2. GlobalData Healthcare. Number of pipeline drugs in the US by therapy area. Pharmaceutical Technology https://www.pharmaceutical-technology.com/comment/number-pipeline-drugs-us-therapy-area/ (2017).
3. Cherny, N. I. et al. ESMO-magnitude of clinical benefit Scale version 1.1. Ann. Oncol. 28, 2340–2366 (2017).
4. Schnipper, L. E. et al. Updating the American Society of Clinical Oncology value framework: revisions and reflections in response to comments received. J. Clin. Oncol. 34, 2925–2934 (2016).
5. Vivot, A. et al. Clinical benefit, price and approval characteristics of FDA-approved new drugs for treating advanced solid cancer, 2000–2015. Ann. Oncol. 28, 1111–1116 (2017).
Cited by
58 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献